Besides, to evaluate the capability in controlling systemic inflammation response mediated by the mIL‐6R mAb treatment, we measured the levels of pro‐inflammatory cytokines in serum including TNF‐α, IL‐1β, IL‐6, and interferon‐γ (IFN‐γ) of the indicated groups 6 h after the treatments, because increased levels of pro‐inflammatory cytokines in serum is the prominent characteristic in the SIRS/sepsis model. This evidence concerns the gene IL6 and systemic inflammatory response syndrome.